Vaccines with enhanced immune response and methods for their...

Details Vaccines with enhanced immune response and methods for their... Vaccines with enhanced immune response and methods for their...

2008-11-20

2010-11-02

Minnifield, N. M (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

C424S450000, C424S455000, C424S278100, C424S812000, C424S193100, C424S283100, C424S689000, C424S690000, C424S698000, C514S002600, C514S937000

Reexamination Certificate

active

07824686

ABSTRACT:
The present invention is concerned with vaccines and their preparation. An effective long-term immune response, especially in mammals, can be produced using a vaccine comprising an antigen encapsulated in liposomes, a suitable adjuvant and a carrier comprising a continuous phase of a hydrophobic substance. The vaccine is particularly effective in eliciting the production of antibodies that recognize epitopes of native proteins.

REFERENCES:
patent: 5015476 (1991-05-01), Cochrum et al.
patent: 5340588 (1994-08-01), Domb
patent: 5422109 (1995-06-01), Brancq et al.
patent: 5637300 (1997-06-01), Dunbar et al.
patent: 5709879 (1998-01-01), Barchfeld et al.
patent: 5736141 (1998-04-01), Brown et al.
patent: 5820879 (1998-10-01), Fernandez et al.
patent: 5897873 (1999-04-01), Popescu
patent: 5910306 (1999-06-01), Alving et al.
patent: 5919480 (1999-07-01), Kedar et al.
patent: 5980898 (1999-11-01), Glenn et al.
patent: 6090406 (2000-07-01), Popescu et al.
patent: 6093406 (2000-07-01), Alving et al.
patent: 6110492 (2000-08-01), Alving et al.
patent: 6168804 (2001-01-01), Samuel et al.
patent: RE37224 (2001-06-01), Brown et al.
patent: 6309569 (2001-10-01), Farrar et al.
patent: 6406719 (2002-06-01), Farrar et al.
patent: 6534064 (2003-03-01), O'Hagan et al.
patent: 6537966 (2003-03-01), Duan et al.
patent: 6565777 (2003-05-01), Farrar et al.
patent: 6670195 (2003-12-01), Ghiso et al.
patent: 6790457 (2004-09-01), Brown et al.
patent: 6793923 (2004-09-01), Brown et al.
patent: 6982314 (2006-01-01), Rosey et al.
patent: 7056515 (2006-06-01), Brown et al.
patent: 7087236 (2006-08-01), Brayden
patent: 7122191 (2006-10-01), Dominowski et al.
patent: 7604802 (2009-10-01), O'Hagan et al.
patent: 2002/0110568 (2002-08-01), Brown et al.
patent: 2004/0258701 (2004-12-01), Dominowski et al.
patent: 2005/0019339 (2005-01-01), Brown et al.
patent: 2005/0220814 (2005-10-01), Dominowski et al.
patent: 2009/0017057 (2009-01-01), Chen et al.
patent: 2009/0035266 (2009-02-01), Schlom et al.
patent: 2009/0074853 (2009-03-01), Brown et al.
patent: 2009/0081244 (2009-03-01), Glenn et al.
patent: 2009/0092666 (2009-04-01), Brown et al.
patent: 2009/0124549 (2009-05-01), Lewinsohn et al.
patent: 2009/0169636 (2009-07-01), O'Hagan et al.
patent: 2523032 (2007-04-01), None
patent: 2542212 (2007-04-01), None
patent: 1948225 (2008-07-01), None
patent: 2134869 (1984-08-01), None
patent: WO 92/00081 (1992-01-01), None
patent: WO 93/25231 (1993-12-01), None
patent: WO 00/37100 (2000-06-01), None
patent: WO 02/38175 (2002-05-01), None
patent: WO 03/066680 (2003-08-01), None
patent: WO 2007/041832 (2007-04-01), None
patent: WO 2007/071707 (2007-06-01), None
patent: WO 2007/071710 (2007-06-01), None
patent: WO 2007/071711 (2007-06-01), None
Tiwari et al, J. Microencapsul., Feb. 2009, 26/1:75-82 Abstract only.
Mansour et al, Clin. and Vaccine Immunol., Oct. 2007, 14/10:1381-1383.
Lambros et al, J. Pharmaceutical Sciences, Sep. 1998, 87/9:1144-1148.
Richards et al, J. Pharmaceutical Sciences, Dec. 1996, 85/12:1286-1289.
Liang et al, Current Drug Delivery, 2006, 3:379-388.
Wiesmuller et al, Biol. Chem., Apr. 2001, 382:571-579.
Cox et al, Vaccine, Feb. 1997, 15/3:248-256.
Alving, Vaccine, (2002) p. S56-S64, vol. 20.
Bagavant et al. “Antifertility effects of porcine zona pellucida-3 immunization using permissible adjuvants in female bonnet monkeys (Macaca radiata); reversibility, effect on follicular development and hormonal profiles”, J. Reprod. Fertil., (1994) p. 17-25, vol. 102.
Brown et al., “Temproal trends in antibody production in captive grey seals, harp and hooded seals to a single administration immunocontraceptive vaccine”, J. Reproductive Immunology, (1979) p. 53-64, vol. 35.
Connejero-Lara, Protein Sci., (1996) p. 2583-2591, vol. 5.
Cox et al., Vaccine, (1997) p. 248-256, vol. 15, No. 3.
Daftarian et al., Vaccine, (2006) p. 5235-5244, vol. 24.
Edelman et al., Intern. Rev. Immunol., (1990) [.51-66, vol. 7, No. 1.
Frezard, F., “Liposomes: From biophysics to the design of peptide vaccines”, Braz. J. Med. Bio. Res., (1999) p. 181-189, vol. 32.
Gregoriadis, G., “Immunological adjuvants: A role for liposomes”, Immunol.,Today, (1990) p. 89-97, vol. 11.
Gupta et al., Vaccine (1993)p. 293-306, vol. 11, No. 13.
Gupta, R., et al., “Adjuvants for human vaccines—current status, problems and future prospects”, Vaccine, (Oct. 1995) p. 1263-1276, vol. 13, No. 14.
Hilbert, A. et al., “Biodegradable microspheres containing influenza A vaccine: immune response in mice”, Vaccine, (Mar. 1999) p. 1065-1073, vol. 17, No. 9-10.
Husband, Vaccine (1993) p. 107-112, vol. 11, No. 2 (Abstract only).
Ivanova et al., “Contraceptive potential of porcine zona pellucida in cats”, Theriogenology, (1995)p. 969-981, vol. 43.
Jentoft, N., et al., “Labelling of proteins by reductive methylation using sodium cyanoborohydride”, J. Biol. Chem., (1979) p. 4359-4365,vol. 254.
Kersten et al., Expert Rev. Vaccines, (2004)p. 453-462, vol. 3, No. 4.
Mosby's Medical, Nursing & Allied Health Dictionary, Sixth Edition, p. 1638 (2002).
Muderhwa et al., “Oil-in-water liposomal emulsions: Characterizations and potential use in vaccine delivery”, J. Pharm. Sci., (Dec. 1999) p. 1332-1339, vol. 88, No. 12.
Muttilainen et al., Microbial Pathogenesis, (1995) p. 423-436, vol. 18.
Nash, H., et al., “Formulation of a potential antipregnancy vaccine based on the beta-subunit of human chorionic gonadotropin (beta hCG). II. Use of compounds of the muramyl dipeptide (MDP) family as adjuvants”, Journal of Reproductive Immunology, (1985) p. 151-162, vol. 7, No. 2.
O Hagan, New Generation Vaccines, ed. Myron M. Levine et al., (2004) p. 259-270, Marcel Dekker, New York.
Parrado et al., Protein Sci., (1996) p. 693-704, vol. 5.
Pye, D. et al., “Selection of an adjuvant for vaccination with the malaria antigen, MSA-2”, Vaccine, (Jun. 1987) p. 1017-1023, vol. 15, No. 9.
Sacco et al., “Effect of varying dosage and adjuvants on antibody response in squirrel monkeys (Saimiri sciureus) immunized with the porcine zona pellucida Mr=55,000 glycoprotein (ZP3)”, Am. J. Reprod. Immunol., (1989) p. 1-8, vol. 21.
Schijns, Current Opinion in Immunology, (2000) p. 456-463, vol. 12.
Teuten et al., Biochem. J. (1993) p. 313-319, vol. 290.
The National Wildlife Research Center web site, www.aphis.usda.gov/ws
wcr/pzp.htm, “Porcine Zona Pellucida Immunocontraception in Mammals”, Jan. 14, 2002.
Torrens et al., Immunology Letters, (1999) p. 213-218, vol. 70.
Willard et al., “Pregnancy detection and the effects of age, body weight, and previous reproductive performance on pregnancy status and weaning rates of farmed fallow deer (Dama dama)”, J. Animal Science, (1999) p. 32-38, vol. 77.
Zauner et al., Bil. Chem., (Apr. 2001) p. 581-595, vol. 382.

Affiliated with

Also associated with

Rating

Vaccines with enhanced immune response and methods for their... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Vaccines with enhanced immune response and methods for their..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccines with enhanced immune response and methods for their... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4229924